Monday, April 28, 2014

Max Compensation



Compensation - Pad your pockets


Max International was founded as a way to bring the life-changing benefits of our glutathione-supporting products to the world, and we can't do it alone. We're looking for determined and motivated individuals to partner with. The Max Compensation Plan outlines the opportunity our partners have to find their unique path and reach their personal income goals – some extra cash every month, enough for a car payment, or even enough to be financially independent. It's your life, we just want to help make it better. Even your Preferred Customers can benefit through the Max Friends & Family Program



Weekly Bonus Commissions

Weekly Bonus Commissions are those commissions which are paid out on the following Wednesday of the week they were earned. Weekly Bonus Commissions include any retail sales, the Preferred Customer Bonus, and the FastTrack Bonus.

Retail Commissions

Associates can purchase products at wholesale for personal use or to resell to customers for a profit. When you buy a product at wholesale and sell at the retail price, you keep the difference. Retail products can be purchased directly from Associates or online at Max.com.

Preferred Customer Bonus

All active Associates are paid a full 25% bonus on every order placed by their personally enrolled Preferred Customers. This is in addition to receiving the 50% Personal Volume (PV) of the dollar value for the orders placed by a Preferred Customer. To qualify for Preferred Customer Bonus, each Associate must have earned a minimum of 50 PV (Active) within the five calendar weeks immediately preceding the customer's order date. Your Preferred Customers can also benefit from the Max Friends & Family Program.

FastTrack Bonus

The FastTrack Bonus consists of a special cash and CV amount from ordering one of our designated Product Packs. When you sell one of these Packs to people you've enrolled, you can receive a bonus check from Max every week! As an additional feature, when you order one of these packs yourself you also earn unique benefits.

Monthly Bonus Commissions

The Monthly Bonus Commissions are the most rewarding parts of our compensation plan and provide long-term residual income. Associates who effectively build their Binary Sales Tree and actively enroll new Associates in their Enrollment Tree will see a sharp increase in their Monthly Bonus Commissions over time.

Double FastTrack Bonus

The Double FastTrack Bonus is a special added bonus earned when a Qualified Associate has three or more of their personally sponsored Associates purchase a Premiere or a Professional Pack within a calendar month.

Team Bonus

All Qualified Associates will earn 10% of the total CV that the Pay Leg of their Binary Sales Tree generates per month. Associates can earn a maximum of $25,000 USD in Team Bonus per month. No more than 250000 CV will be carried forward in the Strong Team from month to month

To qualify for Team Bonuses, you must generate 100 PV and enroll a minimum of two Associates who remain active (with a minimum of 50 PV each month). Both Associates must be evenly placed on your Binary Sales Tree, with one placed on the left sales team and the other on the right sales team. If you do not meet these requirements then your CV will accumulate in both legs as long as you generate 50 PV each month.

Matching Check Bonus

The Matching Check Bonus (MCB) has, by far, the greatest earning potential of all the different commissions. You have the opportunity of receiving the MCB on every personally sponsored Associate as well as on all the Associates that your downline enrolls (and on and on) through seven 'generations.' The MCB is paid on the Team Bonus of the people in your Enrollment Tree up to the 7th generation. Each personally enrolled Associate within your enrollment tree is considered 1st generation. Subsequently, when a personally enrolled Associate enrolls a new Associate, that new Associate becomes your 2nd generation, and so on through the 7th generation.

Global Bonus Pool

Two percent (2%) of the company's global CV is put into a Global Bonus Pool and is paid to Qualified Associates. For each 1,000 CV that an Associate's Pay Leg volume grows compared to the prior month, the Associate will receive one share in the Global Bonus Pool.

Platinum & Diamond Pools

0.75% of the monthly global CV is put in two separate pools and is paid exclusively to Associates who are Platinum, Diamond and above. 0.50% is put in the Platinum Pool. 0.25% is put in the Diamond Pool.

Max Living Bonus

Rather than forcing Associates to buy or lease a car, Max believes in helping Associates achieve what matters most to them. The Max Living Bonus makes it easier for you to fulfill your wants and needs—financial security, a memorable vacation with family, or anything else important to you. We want you to use the Max Living Bonus to help you realize your dreams. The Max Living Bonus can help make it all possible. In order to receive a Max Living Bonus, Associates must have a paid rank of Platinum or above.

Sunday, April 27, 2014

Dr. Robert Keller Resume






— Robert H. Keller, MD, MS, FACP, AAHIVS

Education and Training:
  • 1966 Bachelor of Arts in Biology Master of Science in Biology Fordham University, Bronx, New York
  • 1966 Bachelor of Arts in Biology Master of Science in Biology Fordham University, Bronx, New York
  • 1970 Doctor of Medicine (MD) with honors Temple University, Philadelphia, Pennsylvania
  • 1970-1974 Internship, Resident and Senior Resident University of Rochester, Rochester, New York
  • 1974-1976 Fellow and Senior Fellow Department of Immunology Mayo Clinic, Rochester, Minnesota
  • 1976 Master of Science in Immunology Mayo Graduate School of Medicine Rochester, Minnesota
Professional and Faculty Positions:
  • 2006 Founder, CSO and Director of Medicine KBK Institute of Advanced Medicine Hollywood, Florida
  • 2001 Founder, Chairman, CEO & CSO Phoenix BioSciences which has developed a new first in class and first in man viral-host interaction inhibitor for HIV / AIDS
  • 1999 Founder, Chairmain,CEO and CSO Vitimmune, Inc Hollywood, Florida
  • 1998 Voluntary Adjunct Professor Miller School of Medicine, University of Miami Miami, Florida
  • 1996 Chairman and CEO Immune Balance Technologies Hollywood, Florida
    1994-2006 Director of Medicine & Research BIODORON Medical Center Hollywood, Florida
  • 1994-1995 Consultant in Immunology and Hematology Health Professionals, Inc and Center for Special Immunology
  • 1992-1995 Director Immune Reconstitution Program Center for Special Immunology
  • 1992-1995 Medical Director Center for Special Immunology Miami Beach, Florida
  • 1987-1996 President and Medical Director The Wilson Bode Center Fort Lauderdale, Florida
  • 1986-1987 Associate Director of Research and Development Coulter Immunology Coulter Electronics, Inc., Hialeah, Florida 
  • 1982-1986 Medical Director Wilson Bode Center for Hematology and Immunology Research Milwaukee, Wisconsin 
  • 1982-1986 Clinical Professor Department of Health Sciences (Hematology, Immunology, Flow Cytometry) University of Wisconsin Milwaukee, Wisconsin 
  • 1982-1986 Associate Professor Departments of Medicine and Biophysics Medical College of Wisconsin Milwaukee, Wisconsin 
  • 1982-1986 Clinical Investigator and Staff Physician Zablocki VAMC Milwaukee, Wisconsin 
  • 1980-1982 Director of Immunology Midwest Children's Cancer Center (Immunology, Flow Cytometry, Transplantation) Chief of Immunology Milwaukee Children's Hospital Milwaukee, Wisconsin 
  • 1980-1982 Associate Professor Department of Pediatrics (Hematology/Oncology, Immunology) Medical College of Wisconsin Milwaukee, Wisconsin 
  • 1979-1982 Clinical Associate Professor Department of Health Sciences (Hematology, Immunology, Flow Cytometry) University of Wisconsin Milwaukee, Wisconsin 
  • 1978-1980 Research Associate and Staff Physician Research Service Zablocki VAMC Milwaukee, Wisconsin 
  • 1977-1980 Assistant Professor Department of Medicine (Hematology/Oncology) Medical College of Wisconsin Milwaukee, Wisconsin 
  • 1977 Consultant And Assistant Professor Department of Immunology Mayo Medical School Dept. of Medicine University of Minnesota 
  • 1974-1977 Fellow and Senior Research Fellow in Immunology Mayo Clinic Foundation Mayo Graduate School of Medicine Rochester, Minnesota 
Hospital Staff Appointments:
  • 1976-1977  Mayo Clinic, Rochester, Minnesota 
  • 1977-1986  Zablocki VAMC, Milwaukee, Wisconsin 
  • 1977-1986  Milwaukee County Medical Complex, Milwaukee, Wisconsin 
  • 1992-1997  Mount Sinai Medical Center, Miami Beach, Florida 
  • 1992-1999  Cleveland Clinic Hospital, Fort Lauderdale, Florida 
  • 1992-1999  Miami Heart Institute, Miami Beach, Florida 
  • 1997-1999  Palmetto General Hospital, Hialeah, Florida 
  • 1997- 2005  South Shore Hospital, Miami Beach, Florida 
  • 1997- 2005  Memorial Medical Center, Hollywood, Florida 
  • 1992-  Broward General Medical Center, Fort Lauderdale, Florida 
  • 1997-  Hollywood Medical Center, Hollywood, Florida 
Fellowships and Awards:
  • 1997-  Hollywood Medical Center, Hollywood, Florida  1967-1969  Health Professions Scholarship
  • Temple University School of Medicine 
  • 1974-1975  Mayo Foundation Research Fellowship
  • Mayo Graduate School of Medicine 
  • 1975-1978  National Arthritis Foundation Fellowship 
  • 1978-1981  VA Career Development Award, Research Associate 
  • 1983-1986  VA Career Development Award, Clinical Investigator 
Grant Support during Academic Tenure
  • 1978-1980  Alpha-fetoprotein Immunoregulation in a Model of Murine Lymphoma Veterans Administration Research Principal Investigator  $210,000 
  • 1981-1986  Immunoregulatory Dysfunction in Non-Hodgkin's Lymphoma NIH, NCI Principal Investigator  $430,000 
  • 1982-1986  Immunologic Studies of Environmental Lung Disease NIH (NIAID) Co-Principal Investigator  $525,000 
  • 1983-1986  VA Career Development Award Clinical Investigator  $240,000 
  • 1984-1986  Clinical Applications of Laser Flow Cytometry Principal Investigator NIH (RR Shared Equipment Program)  $105,609 
  • 1984-1987  Immunoregulatory Dysfunction Principal Investigator VA  $245,000 
  • 1985-1986  Monoclonal Antibodies in the Detection of Cervical Carcinoma Co-Principal Investigator Hillman Foundation  $85,000 
  • 1986-1987  Isoprinosine Modulation of the Immuno- Regulatory Imbalances in AIDS and ARC Principal Investigator of FDA IND Newport Foundation  $125,000 
  • 1986-1987  Isoprinosine Modulation of the Immuno- Regulatory Imbalances in AIDS and ARC Principal Investigator of FDA IND Newport Foundation  $125,000 
Honors:
  • 1970  Alpha Omega Alpha Temple University, School of Medicine 
  • 1970  Medical Degree with honors Temple University, School of Medicine
  • 1979  Superior Performance Award in Research Veterans Administration
  • 1980  Fellow, American College of Physicians 
  • 1991  Who's Who in Science and Technology 
  • 1994  Who's Who in the World 
  • 1996  Who's Who in Medicine and Science 
  • 1998  HIV Medical Professional of the Year PWAC, Broward County, Florida 
  • 1999  Humanitarian of the Year National Hemophilia Foundation 
  • 2001  2000 Outstanding Scientists of the 21st Century 
  • 2002  1000 Great Americans of the 21st Century 
  • 2003  America's Top Physicians in Internal Medicine, Immunology and Hematology 
  • 2004  Elected to Board of Governors  Academy of HIV Medicine of the State of Florida:
  • 2004  AMA Physicians Recognition Award 
  • 2005  Greatest Scholars of the Twenty First Century 
  • 2006  Health Professional of the Year Invited Lectureships: 
  • 1977  Second Fogarty International Conference on Neonatal Liver Disease Baltimore, Maryland 
  • 1977  International Conference on the Diagnosis and Prevention of Neural Tube Defects Los Angeles, California 
  • 1977  Second International Conference on Diagnostic Immunology Henniker, New Hampshire 
  • 1979  Radio immunochemical Detection of Cancer Albuquerque, New Mexico 
  • 1980  Visiting Professor of Hematology University of Mississippi Jackson, Mississippi 
  • 1981  Visiting Professor of Hematology University of California Irvine, California 
  • 1981  Third International Conference on Diagnostic Immunology, Section Chair 
  • 1982  Visiting Professor of Pathology University of Texas Medical Branch Galveston, Texas 
  • 1983  Visiting Professor of Medicine Wilfred Hall Air Force Research Center Galveston, Texas 
  • 1984  Visiting Professor Max Plank Institute for Biochemie Munich, Germany 
  • 2005  Visiting Professor of Immunology and Pharmacology Peking Union Medical School (University of Beijing) Beijing, China
Editorial Boards:
  • 1986-1990  Diagnostic Immunology 
  • 1984-1986  Journal of Leukocyte Biology 
  • 2005  Interventions in Aging 
Reviewer:
  • 1990-Present  Journal of Immunology 
  • 2005  Interventions in Aging 
Consultant ships:
  • Coulter Epics 
  • Coulter Immunology 
  • Corning Scientific 
  • National Aeronautics and Space Administration (NASA) 
  • Abbott HIV Advisory Board 
  • Baxter Advisory Board for Hemophilia 
  • Baxter Advisory Board for Hemophilia Inhibitor Patients 
  • Consultant in Cancer Therapy, PRSS-J, Tokyo, 2005 
  • Medical Advisory Council, American Federation of Hemophilia, 2002 
Board of Director Appointments:
  • 2006  Member American Academy of HIV Medicine 
  • 2006  Member Biosource Therapeutics 
  • 2001  Chairman, Phoenix Bioscience 
  • 1999  Chairman, VitImmune 
  • 1996  Chairman, IBT 
  • Scientific Advisory Boards:
  • 2006  Cytodyn Inc 
  • 2006  Acthelon Medical 
  • 2006  Bioscource Therapeutics 
Certifications:
  • National Board of Medical Examiners, 1971 and 1990 
  • American Board of Internal Medicine, 1974 
  • American Academy of HIV Medicine, 2001 
  • American Academy of Anti Aging Medicine 2006 
Current Medical Licensure:
  • New York  #112195 
  • Wisconsin  #19121 
  • Florida  #58991 
Certification:
  • ACLS  1990 
  • ATLS  1990 
Professional Societies:
  • Alpha Omega Alpha 
  • American Association for the Advancement of Science 
  • American Association of Immunologists 
  • American College of Physicians 
  • American Federation of Clinical Research 
  • American Society of Clinical Pathology 
  • American Society of Hematology 
  • International Society of Hematology
  • International Society of Hematopathology 
  • International Immunocompromised Host Society 
  • International Society of Analytical Cytology 
  • Clinical Cytometry Society 
  • New York Academy of Sciences 
  • Clinical Immunology Society 
  • National Organization for Rare Disorders 
  • American Academy of Anti Aginig Medicine 
Teaching Experience:
  • 1978-1980  Survey in Basic and Clinical Immunology Department of Medicine Medical College of Wisconsin 
  • 1980-1983  Principles of Laser Flow Cytometry Department of Health Sciences University of Wisconsin 
  • 1981  Special Topics in Immunology Immunoregulation in Cancer Department of Biology Marquette University 
  • 1983-1986  Co-Director Flow Cytometry Program University of Wisconsin Introduction to Flow Cytometric Analysis Principles of Image and Laser Cytometry Hybridomas and Monoclonal Antibodies Laboratory Evaluation of Immunoregulation Clinical Immunophenotyping and DNA Analysis Advanced Cytometry Advanced Cytometric Techniques 
Invited Professional Lectures:
  • Since 1979 - Dr. Keller has been the invited speaker at more than 2500 state, regional, National, and international, medical and scientific seminars and workshops In the fields of:
    •     AIDS and Immunoregulation
    •     Clinical Immunology
    •     Chronic Fatigue Syndrome and Fibromyalgia
    •     Autoimmune Disease and Control of Aberrant Immune Response
    •     Nutrition and the Immune Response
    •     Hormones and the Immune Response
    •     Hepatitis C
    •     Hemophilia
    •     Protecting the Immune System Before, During, and After
          Cancer Therapy
    •     Age Management
  • 2000-2002  Host of Today's Health, WAXY 790 and Web streamed at Vitimmune.com and RobKellermd.org 
  • 2005-2006  Host of Voice America Web Based Interactive Radio Show, The Path to Wellness and Youth 
Committee Service:
  • 1985-1986  Veterans Administration Development Research and Committee Clement J. Zablocki  VAMC
  • 1986-1989  VA Oncology Merit Review Board 
  • 1984-1986  International Society For Analytical Cytology: Research and Development 
  • 1983-1986  Controls & Standards University of Wisconsin: Co Chair Flow Cytometry 
  • 1983-1986  National Institutes of Health: Special Immunology Review Council Study Section 
  • 1980-1982  Medical College of Wisconsin Faculty Welfare Committee 
  • 1980-1982  Animal Care Committee 
  • 1982-1986  Flow Cytometry Protocol Committee 
  • 1992  Cancer Committee for Hollywood Medical Center 
  • 1998  Committee of Ten Thousand Medical Advisory Board 
  • 1996  National Hemophilia Federation: Medical Advisory Committee 
  • 1994  National Hemophilia Foundation- Florida Chapter Medical Advisory Committee 
  • 1994-1997  Mount Sinal Medical Center Cancer Committee 
  • 2001  Hollywood Medical Center Cancer Committee 
  • 2005  Underwriting Committee ProAssurance Malpractice 
  • 2005  AAHIVM Standards of Practice Committee 
  Statement of Research Interest:
  • HIV: Dissection of the immune perturbations Associated with HIV infection including therapy with experimental immunomodulary agents. 
  • Dissection of the immune perturbations Associated with hemophiliac complication and therapeutic intervention using experimental immunoregulatory agents. 
  • Creation and utilization of unique `designer` monoclonal antibodies for the diagnosis, monitoring, imaging and therapy of human hematologic and solid tumor malignancies. 
  • Immune response and immunoregulation: dissection of the basic human immune response and the roles of cytokines and other regulatory molecules and the demonstration and characterization of aberrant responses in neoplastic and immunologic disease. 
  • Nutritional/ Hormonal Supplementation in Age Management and Immunologic Disease 
  Patents Issued:
  • R.H. Keller and Dr. X. Wen: Allerg-ease (Patent Number 6,180,106) (2000) 
  • R.H. Keller, D.W. Kirchenbaum: ALL-Immune (Patent Number 6,262,019) (2002) 
  • R.H. Keller, PBS 119 a novel treatment for chronic viral infections (Patent Number 6,734,192) (2004) 
  Patents Pending:
  • Keller R.H. A novel treatment For Viral Infections (CIP) 2005 
  • Keller RH: An improved method for glutathione production in mammals 2007 
  • Keller RH: A nutritional formula to promote weight loss in mammals 
  • Keller RH: A novel treatment for neurodegenerative diseases 
  • Keller RH: A nutritional formula to improve short term memory function 
  Books:
  • Keller, R.H. After Thirty, Some Maintenance Is Required-A Practical Guide to Age Management 
  Book Chapters:
  • Keller, R.H. and Tomasi, T.B.: Alpha-fetoprotein: A Potential Regulator of Immune Function. In Diseases of the Liver and Biliary Tract. Javitts, N.NIH, Bethesda, Maryland, pp. 119-134, 1977. 
  • Keller, R.H., Calvinico, N.J., Fink, J.N., and Stevens, J.O.: Immunobiologic Aspects of Primate Hypersensitivity Pneumonitis. In Environmental Toxicology. Dungworth, D.L. (Ed), Academic Press, New York, pp.383-395, 1981. 
  • Keller, R.H., Blake, D.G., Lyman, S. and Siebenlist, R.: The Immunobiology of Human Non-Hodgkin's' Lymphomas. In Clinical Cellular Immunology. Ludered, A. (ed). Humana Press, New York, pp. 213-246, 1982. 
  • Patrick, C.W., Keller, R.H., and Horan, P.K.: Flow Cytometry, Cell Sorting and Hybridomas. American Society Clinical Pathology Press. St. Louis, MO, pp. 1-182, 1982. 
  • Patrick, C.W., Parker, J., Keller, R.H., and Horan, P.K.: The Clinical Utility of Monoclonal Antibodies and Immunophenotyping. In Flow Cytometry and Cell Sorting in Hematologic Disease. American Society of American Pathologists Press. Chicago, IL pp. 1-191. 
  • Calvinico, N.J., Fink, J.N., and Keller, R.H.: Hypersensitivity Pneumonitis. In The Immunology of the Lung. Bienenstock, J. (Ed), Academic Press, New York pp 365-366, 1984 
  • Keller, R.H., Milson, T.J., Janicek, K.M., Patrick, L.C., Sohnle, P., and Patrick, C.W.: Clinical Utilization of the Technicon H-6000 Flow Cytochemical Flow System in Allergy Testing. In Proceedings of the 4th International Technicon Hematology Colloquium. Simson, E. (ed) Academic Press, New York, pp 179- 188, 1984. 
  • Patrick, C.W., Horan, P.K, and Keller, R.H.: Immunophenotypic and Functional Analysis Using Laser Flow Cytometry: Clinical Utility. American Society of Clinical Pathology Press, Chicago, IL, 1985, pp. 1-168. 
  • Patrick, C.W. and Keller, R.H.: Lymphocytes: Biochemistry, Physiology, Function and Morphology. In Principles of Hematology: Clinical and Laboratory Practice. R.L. Bick, (Ed) C.V. Mosby, St. Louis, MO in press. 
  • Patrick, C.W. and Keller, R.H.: The Emerging Role of Laser Flow Cytometry and Monoclonal Antibodies in Clinical Medicine. In: Principles of Hematology: Clinical Laboratory Practice. R.L. Bick (Ed) C.V. Mosby, St. Louis, MO, in press. 
  • Keller, R.H. and Patrick, C.W.: Characterization of the Human Myeloid Series by Monoclonal Antibodies. In Monoclonal Antibodies in Laboratory Medicine. Swartz, M. (Ed) Academic Press, New York, in press. 
  • Patrick, C.W., McFadden, P.W., and Keller, R.H.: Immunophenotypic Analysis of Human Bone Marrow Employing Monoclonal Antibodies and Laser Flow Cytometry. In Proceedings of the Second International Conference on Technological Advances in Laboratory Hematology. Howen, B. (ed),Academic Press, 1985. 
  • Keller, R.H., Janicek, K.M., and Patrick, C.W.: The Clinical Significance of Laser Flow Cytometry DNA Analysis. In Proceedings of the Second International Conference on Technological Advances in Laboratory Hematology. Howen, B. (Ed) Academic Press, New York, 1985. 
  • Keller, R.H., Van Riel, F., Maislis, J., Lane, J.T., Reiter, W.M., Klimas, N.G, Fletcher, M.A.: Association of Histocompatability Class II Antigens wit the Chronic Fatigue Immune Dysfunction Syndrome. In Clinical Infectious Disease. University of Chicago, Chicago, IL, 1994:18 (Supp 1): S154-6. 
  • Antioxidants and the skin, A Paradigm for aging. Keller, R.H and E Arrayove (in press) 2004. glutathione in Aging and Immunologic Disease. Loss of Gastrointestinal During Aging and Immunologic Disease Both Ed R. Wallace and Mechanisms of Aging Dove Press N Z, 2006 
  • Original Research Contributions and Invited Reviews: Keller, R.H. and Tomasi, T.B.: Alpha-fetoprotein, E-Rosette Formation and Tumor Cell Growth. N Engl J Med 293(24): 1265-1266, 1975. 
  • Tomasi, T.B., Dattwyler, R., Murgita, R. and Keller, R.H.: Immunosuppression By Alpha-fetoprotein. Trans Am Assoc Phys. 88:293-298, 1976. 
  • Geubel, A.P., Keller, R.H., Summerkill, W.H.J., Dickson, E.R., Tomasi, T.B. and Shorter, R.G.: Lymphocyte Cytotoxicity and Inhibition Studied with Autologous Liver Cells: Observation in Chronic Acute Liver Disease and the Primary Biliary Cirrhosis Syndrome. Gasterenterol. 71:450-459, 1976. 
  • Keller, R.H. and Clavanico, N.J., and Tomasi, T.B.: Immunosuppressive Properties of AFP: Role of Estrogens. In Onco Developmental Gene Expression. Fichman, W.H. and Sell, S. (eds) Academic Press, New York, p.278, 1976. 
  • Keller, R.H. and Tomasi, T.B.: Synthesis of Alpha-fetoprotein by Murine Lymphoid Cells in Allogenic Reactions. J Exp Med 143:1120, 1976. 
  • Banks, P., Keller, R.H., Li, V.Y. and White, E.B.: Malignant Lymphomas of Plasmablastic Identity: A Neoplasm with Both "Immunoblastic" and Plasma Cell Features. Am J Med 64:609-610, 1978. 
  • Keller, R.H., Atwater, J.S., Martin, R.S. and Tomasi, T.B.: Ataxia Telangiectasia, Immunosuppression and AFP: Is There a Relationship? In Prevention of Neural- Tube Defects. Crandall, B. (ed) Academic Press, New York, pp.27-40, 1978. 
  • Guirgis, H.A., Lynch, H.T., Keller, R.H., Tomasi, T.B., Vandervoorde, J., Brodky, F., Lynch, J., Rankin, L. and Malony, K.: Carcinoembryonic Antigen (CEA) and Alpha-fetoprotein (AFP) in Cancer-Prone Families: Communicable Implications. In Proceeding of the Third Annual Symposium on the Detection and Prevention of Cancer. Part I (2), 1987. 
  • Keller, R.H., Dattwyler, R.J., Harrison, E. and Tomasi, T.B.: Alpha-fetoprotein in Human Lymphoproliferative Disease. J Lab Clin Immunol, 2:93-98, 1979. 
  • Kaplan, H.J., Meredith, T.A., Aeberg, T.M. and Keller, R.H.: Intraocular Reticulum Cell Sarcoma (Histiocytic Lymphoma) in Richter's Syndrome: A Neoplasm of the Immune System. Arch Opthal 98:707-710, 1980. 
  • Keller, R.H., Blake, B.G., Lyman, S. and Siebenlist, R.: ImmunoregulatoryAbnormalities in Chronic Lymphocytic Leukemia. J Lab Clin Immunol 6:201-208, 1981. 
  • Choi, H. and Keller, R.H.: Co-existence of Chronic Lymphocytic Leukemia and Hodgkin's Disease. Cancer 48:48-55, 1981. 
  • Kaplan, H.J., Aeberg, T.M. and Keller, R.H.: Etiology of Recurrent Clinical Uveitis. Ber Dtsch Ophthal Ges 78:159, 1981. 

Creators




The creator of RiboCeine™ - Herbert T. Nagasawa, Ph.D., Executive Research Scientist

Chief Scientist and co-founder of CellGevity, Inc., Dr. Nagasawa received his B.S. degree in chemistry from Western Reserve University (now, Case-Western Reserve) in Cleveland, Ohio, and the Ph.D. degree in organic chemistry from the University of Minnesota. Subsequently, he spent two years as a Post-doctoral Fellow in biochemistry at the University of Minnesota before joining the research staff of the V.A. Medical Center in Minneapolis as a Senior Chemist. He was appointed Assistant Professor of Medicinal Chemistry at the University of Minnesota in 1959. He was named Principal Scientist of the VAMC in 1961 and was promoted in 1976 to Senior Research Career Scientist, a nationwide VA title reserved for the VA's top scientists. He was promoted to Associate Professor in 1963 and to Professor of Medicinal Chemistry in 1973. He also held joint professorships in the Department of Pharmacology and the university-wide Division of Toxicology, and served as Visiting Professor at Washington State University in 1990. He also served for 32 years as a Senior Editor for the prestigious international Journal of Medicinal Chemistry from 1972 to 2004, and one year as Acting Editor-in-Chief. In addition, he served on the Editorial Board of the journal, Bioconjugate Chemistry for eight years, and as an ad hoc grant reviewer for the NCI and NIAAA, National Institutes of Health. He has published over 165 papers in peer-reviewed journals, and is the inventor named on ten U.S. and PCT patent applications.




The Creator of MaxGXL - Robert H. Keller, MD, MS, FACP

Dr. Keller has served on the scientific review panels for the National Institutes of Health and the VA. The Consumers' Research Council has named him one of America's "Top Physicians in 2003, 2004, 2005, 2006, and 2007 in the fields of Internal Medicine, Immunology and Hematology." Dr. Keller has served on the faculties of the Mayo Graduate School of Medicine, the University of Wisconsin and the Medical College of Wisconsin (Marquette Univ.) He has published more than 100 original articles in various scientific and medical journals and has been awarded several patents. Dr. Keller was elected to The Board of Governors of the American Academy of HIV Medicine.





RiboCeine Research

RiboCeine Research

PLEASE NOTE: The following links take you away from this page to 3rd party research sites. 


Roberts, J.C.; Francetic, D.J.; Zera, R.T. L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity. Cancer Chemotherapy and Pharmacology 1991, 28, 166-170. 


Roberts, J.C.; Francetic, D.J. Mechanisms of Chemoprotection by RibCys, a Thiazolidine Prodrug of L-cysteine. Med. Chem. Res., 1991, 1, 213-219. 

Roberts, J.C.; Charyulu, R. L.; Zera, R.T.; Nagasawa, H.T. Protection Against Acetaminophen Hepatotoxicity by Ribose-Cysteine (RibCys). Pharmacology & Toxicology, 1992, 70, 281-285. 

Rowe, J.K.; Zera, R.T.; Madoff, R.D.; Fink, A.S.; Roberts, J.C.; Johnston, G.R.; Freeney, D.A.;Young, H.L.; Bubrick, M.P.Protective Effect of RibCys Following High-Dose Irradiation of the Rectosigmoid. Dis. Colon Rectum, 1993, 36(7), 681-687. 

Roberts, J.C.;Francetic, D.J.; Zera, R.T. Chemoprotection against Cyclophosphamide-Induced Urotoxicity: Comparison of Nine Thiol Protective Agents. AntiCancer Research, 1994, 14, 389-396. 

Carroll, M.P.; Zera, R.T.; Roberts, J.C.; Schlafmann, S.E.; Feeny, D.A.; Johnston, G.R.; West, M.A.; Bubrick, M.P.Efficacy of Radioprotective Agents in Preventing Small and Large Bowel Radiation Injury. Dis. Colon Rectum, 1995, 38(7), 716-722. 

Roberts, J.C.; Koch, K.E.; Detrick, S.R.; Warters, R.L.; Lubec G. Thiazolidine Prodrugs of Cysteamine and Cysteine as Radioprotective Agents. Radiation Research, 1995, 143, 203-213. 

Bantseev, V.; Bhardwaj, R.; Rathbun, W.; Nagasawa, H.T.; Trevithick, J.R. Antioxidants and Cataract: (Cataract Induction in Space Environment and Application to Terrestrial Aging Cataract). Biochem. Mol. Bio. Intl., 1997, 42, 1189-1197. 

Roberts, J.C.; Phaneuf, H.L.; Szakacs, J.G.; Zera, R.T.; Lamb, J.G.; Franklin, M.R. Differential Chemoprotection against Acetaminophen-Induced Hepatotoxicity by Latentiated L-Cysteines. Chem. Res. Toxicol., 1998, 11, 1274-1282. 

Roberts, J.C.; Phaneuf, H.L.; Dominick, P.K.; Wilmore, B.H.; Cassidy, P.B. Biodistribution of [35S] - Cysteine and Cysteine Prodrugs: Potential Impact on Chemoprotection Strategies. J. Labelled Cpd. Radiopharm., 1999, 42, 485-495. 

Lucus, A.M.; Henning G.; Dominick, P.K.; Whiteley, H.E.; Roberts, J.C.; Cohen, S.D. Ribose Cysteine Protects Against Acetaminophen-Induced Hepatic and Renal Toxicity. Toxicologic Pathology, 2000, 28(5), 697-704. 

Wilmore, B.H.; Cassidy, P.B.; Warters, R.L.; Roberts, J.C. Thiazolidine Prodrugs as Protective Agents against y-Radiation-Induced Toxicity and Mutagenesis in V79 Cells. J. Med. Chem., 2001, 44(16), 2661-2666. 

Lenarczyk, M.; Ueno, A.; Vannais, D.B.; Kraemer, S.; Kronenberg, A.; Roberts, J.C.; Tatsumi, K.; Hei, T.K.; Waldren, C.A. The "Pro-drug" RibCys Decreases the Mutagenicity of High-LET Radiation in Cultured Mammalian Cells. Radiation Research, 2003, 160, 579-583. 

Lucas Slitt, A.M.; Dominick, P.K.; Roberts, J.C.; Cohen, S.D. Effect of Ribose Cysteine Pretreatment on Hepatic and Renal Acetaminophen Metabolite Formation and Glutathione Depletion. Basic Clin. Pharmacol. Toxicol., 2005, 96 (6), 487-94. 

Oz, H.S.; Chen, T.S.; Nagasawa, H., Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model. Translational Research, 2007, 150(2), 122-129. 


Cellgevity™
The ULTIMATE in Glutathione Enhancement
Increasing your glutathione level will naturally increase your energy, detoxify your body and strengthen your immune system.

A 1 month supply of Cellgevity in a bottle. Cellgevity™ provides the ultimate in glutathione enhancement delivering Max's patented ingredient, RiboCeine, and other essential nutrients that support glutathione's vital role in removing harmful toxins, eliminating cellular inflammation, and neutralizing free radical damage in our body.



Visible Solutions™


A Difference You Can See
Advanced Skin Care by Max
Max International® has the skin care solution you need the Visible Solutions™ Skin Care System. Backed by years of research and formulated with the help of skin care experts and scientists, each component of the system utilizes a proprietary anti-aging formula for optimum skin health and vitality. It's exactly what you need to draw the line on looking older.
With Visible Solutions, you can actually see a difference in one minute! This advanced system helps you protect and revitalize your skin like never before so you can look your best every day.






MaxOne™ provides the most advanced glutathione 

support you can find—anywhere. 

MaxOne™—quite simply the most advanced glutathione support you can find, anywhere. MaxOne is powered by exclusive RiboCeine™ technology, which is backed by more than a dozen peer-reviewed articles. When it comes to unsurpassed cellular health, the One, clear choice is MaxOne.